[1]韩秀蕊,杨娣娣,赵 园,等.281例骨髓增生异常综合征患者染色体核型分析及临床意义的研究[J].现代检验医学杂志,2015,30(04):91-92.[doi:10.3969/j.issn.1671-7414.2015.04.025]
　HAN Xiu-rui,YANG Di-di,ZHAO Yuan,et al.Study on Chromosome Karyotype and Its Clinical Significance in 281 Cases of Myelodysplastic Syndromes[J].Journal of Modern Laboratory Medicine,2015,30(04):91-92.[doi:10.3969/j.issn.1671-7414.2015.04.025]
点击复制

281例骨髓增生异常综合征患者染色体核型分析及临床意义的研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年04期
页码:
91-92
栏目:
论著
出版日期:
2015-08-10

文章信息/Info

Title:
Study on Chromosome Karyotype and Its Clinical Significance in 281 Cases of Myelodysplastic Syndromes
文章编号:
1671-7414(2015)04-091-03
作者:
韩秀蕊1; 杨娣娣1; 赵 园1; 张丽洁1; 李艳春1; 王九菊1; 翟欣辉1; 魏绪仓1; 周家琛2
1.陕西省人民医院血液病研究室,西安 710068;
2.大连医科大学,辽宁大连 116044
Author(s):
HAN Xiu-rui1; YANG Di-di1; ZHAO Yuan1; ZHANGLi-jie1;  LI Yan-chun1; WANG Jiu-ju1; ZHAI Xin-hui1; WEI Xu-cang1; ZHOU Jia-chen2
1.Department of Hematology,Shaanxi Provincial People's Hospital, Xi'an 710068,China;
2.Dalian Medical University,Liaoning Dalian 116044,China
关键词:
骨髓增生异常综合征;  染色体核型;  细胞遗传学
分类号:
R551.3; R446.7
DOI:
10.3969/j.issn.1671-7414.2015.04.025
文献标志码:
A
摘要:
目的 探讨骨髓增生异常综合征(MDS)患者染色体核型异常特征及其与临床预后的关系。方法 采用染色体常规G显带技术,对281例MDS患者进行细胞遗传学核型分析。结果 281例MDS患者中,染色体异常核型检出率48.75%(137/281),其中单纯染色体数目异常43.07%(59/137),单纯染色体结构异常者31.39%(43/137),同时有数目与结构异常者25.54%(35/137)。MDS亚型中,RAEB-2异常核型检出率为63.41%(26/41),RAEB-1为58.73%(37/63),RCMD 39.2%(49/125),RAS 15.38%(2/13),RA 22.58%(7/31)。RA,RAS异常核型检出率明显低于RAEB-1和RAEB-2(P＜0.01),RAEB-1和RAEB-2检出率高于RCMD(P＜0.05)。出现频率较高的染色体畸变依次为+8,-7/7q-,-20/20q-,复杂异常核型,染色体易位,i(17),-Y,+21等。随访的159例MDS患者中核型正常者68例,中位生存时间为39个月,核型异常者91例中位生存期21个月的,前者明显长于后者(P＜0.05),分析白血病转化率,核型异常者(35.5%),明显高于核型正常者(10.3%)(P＜0.01),其中以复杂核型、-7/7q-核型较易转为白血病。结论 MDS系克隆性恶性血液病,具有高度异质性,染色体核型检查对MDS的正确诊断、分型和预后判断具有重要意义。
Abstract:
Objective To explore the abnormal karyotype characteristics of myelodysplastic syndrome(MDS)patients and their correlation with clinical prognosis.Methods Analyzed the karyotypes of 281 MDS patients by use of G-banding technique.Results Through analysis of the karyotypes of 281 MDS patients,found that the percentage of abnormal karyotypes was 48.75%(137/281),among 137 patientswith abnormal karyotypes,43.07%(59 cases)presented with numerical aberration,31.39%(43 cases)with structural aberration,and 25.54%(35 cases)with both numerical and structural abnormalities.As for MDS subtypes,the occurrence rate of abnormal karyotype was 63.41%(26/41)in RAEB-2,58.73%(37/63)in RAEB-1,39.2%(49/125)in RCMD,15.38%(2/13)in RAS and 22.58%(7/31)in RA.The rates of abnormal karyotype in RAEB-1 and RAEB-2 were significantly higherthan that in RA and RAS(P＜0.01),and in RCMD(P＜0.05).The frequent abnormal karyotypes were as follows:+8,-7/7q-,-20/20q-,complex karyotypes chromosomal translocation,i(17),-Y and +21.The follow-up study of 159 MDS patients indicated that the median survival time was 39 months for 68 patients with normal karyotypes and 21 months for 91 patients with abnormal karyotypes,the former was significantly prolonged than the latter(P＜0.05).As far as the leukemia transition rate was concerned,the patients with aberrant karyotypes(35.5%)were significantly higher than that with normal karyotypes(10.3%)(P＜0.01),among them,the cases with complex karyotypes and -7/7q- more easily transit into leukemia.Conclusion MDS was one kind of clonal hematological malignancy with high heterogeneity.Chromosomal karyotype test plays an important role in the correct diagnosis,typing and prognosis evaluation of MDS.

参考文献/References:

[1] Bernasconi P,Klersy C,Boni M,et al.World Health Organizationclassification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes[J].Br J Haematol,2007,137(3):193-205.
[2] Vardiman JW,Thiele J,Arber DA,et al.The 2008 revision of the World Health Organization(WHO)classification of myeloid neoplasms and acute leukemia:rationale and important changes [J].Blood,2009,114(5):937-951.
[3] Valent P,Horny Hp,Bennett JM,et al.Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes:consensus statements andreport from a working conference[J].Leuk Res,2007,31(6):727-736.
[4] 李 璘,刘旭平,聂 玲,等.原发性骨髓增生异常综合征染色体核型异常特征及其预后意义的研究[J].中华血液学杂志,2009,30(4):217-222.
Li L,Liu XP,Nie L,et al.Study on karyotypic abnormalities andits prognostic significance in Chinese patients with primary myelodysplastic syndromes[J].Chinese Journal of Hematology,2009,30(4):217-222.
[5] 曲士强,刘旭平,徐泽锋,等.不同细胞遗传学预后分组对原发性骨髓增生异常综合症患者预后意义的研究[J].中华血液学杂志,2011,32(12):819-824.
Qu SQ,Liu XP,Xu ZF,et al.Study on prognostic signficances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes[J].Chinese Journal of Hematology,2011,32(12):819-824.
[6] 吴德沛.骨髓增生异常综合症的预后判断[J].中华血液学杂志,2012,33(7):512-514.
Wu DP.The prognosis of myelodysplastic syndromes[J].Chinese Journal of Hematology,2012,33(7):512-514.
[7] Sole F,Espinet B,Sanz GF,et al.Incidence characterization and prognostic significance of chromosome abnormalities in 640 patients with primary myelodysplastic syndromes.Group cooperativo espanol de citogenetica hematologica[J].Br J Haematol,2000,108(2):346-356.

相似文献/References:

[1]张宇洋,孙雪静.骨髓穿刺涂片联合骨髓活检切片在骨髓增生异常综合征诊断中的应用[J].现代检验医学杂志,2016,31(02):139.[doi:10.3969/j.issn.1671-7414.2016.02.042]
　ZHANG Yu-yang,SUN Xue-jing.Value of Both Bone Marrow Biopsy and Smear in Diagnosis of Myelodysplastic Syndrome[J].Journal of Modern Laboratory Medicine,2016,31(04):139.[doi:10.3969/j.issn.1671-7414.2016.02.042]
[2]聂 群,陈卓诚a,聂李平a,等.自动血细胞分析参数对骨髓增生异常综合征和再生障碍性贫血的鉴别诊断价值[J].现代检验医学杂志,2017,32(05):74.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　NIE Qun,CHEN Zhuo-chenga,NIE Li-pinga,et al.Performance of Automatic Blood Cell Analysis Parameters for Differential Diagnosis of Myelodysplastic Syndromes and Aplastic Anemia[J].Journal of Modern Laboratory Medicine,2017,32(04):74.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[3]唐元艳,张利铭,张江召,等.骨髓增生异常综合征患者染色体异常与细胞形态学的相关性分析[J].现代检验医学杂志,2017,32(06):71.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TANG Yuan-yan,ZHANG Li-ming,ZHANG Jiang-zhao,et al.Correlation between Chromosomal Abnormality and Cell Morphology with Myelodysplastic Syndrome Patients[J].Journal of Modern Laboratory Medicine,2017,32(04):71.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[4]张冬梅,万顺伦,于丽华.骨髓增生异常综合征患者外周血单个核细胞中OTC4，Gli1 基因的表达及与预后的COX 回归分析[J].现代检验医学杂志,2022,37(06):58.[doi:10.3969/j.issn.1671-7414.2022.06.011]
　ZHANG Dong-mei,WANG Shun-lun,YU Li-hua.Expression of OTC4 and Gli1 Genes in Peripheral Blood Mononuclear Cells of Patients with Myelodysplastic Syndrome and Their Correlation with Prognosis by COX Regression Analysis[J].Journal of Modern Laboratory Medicine,2022,37(04):58.[doi:10.3969/j.issn.1671-7414.2022.06.011]
[5]张良子,左琴琴,吴大洲,等.1 例骨髓增生异常综合征多次受血患者血清存在抗-M，抗-cE 和抗-Jkb 抗体的鉴定及配血输血策略[J].现代检验医学杂志,2023,38(01):195.[doi:10.3969/j.issn.1671-7414.2023.01.037]
　ZHANG Liang-zi,ZUO Qin-qin,WU Da-zhou,et al.Identification and Transfusion Strategy of Anti-M，Anti-cE and Anti-Jkb Antibodies in the Serum of Patients with Myelodysplastic Syndromes Receiving Multiple Blood Transfusions[J].Journal of Modern Laboratory Medicine,2023,38(04):195.[doi:10.3969/j.issn.1671-7414.2023.01.037]
[6]曲志梅,董 伟,刘艳萍.维奈克拉增强MDS 细胞系对地西他滨化疗敏感性机制的实验研究[J].现代检验医学杂志,2023,38(03):53.[doi:10.3969/j.issn.1671-7414.2023.03.010]
　QU Zhi-mei,DONG Wei,LIU Yan-ping.Experimental Study on the Mechanism of Venetoclax Enhancing the Sensitivity of MDS Cell Lines to Decitabine Chemotherapy[J].Journal of Modern Laboratory Medicine,2023,38(04):53.[doi:10.3969/j.issn.1671-7414.2023.03.010]
[7]徐 娟a,贲海祥a,丁琳琳a,等.白细胞介素-1β 基因（rs16944）单核苷酸多态性与骨髓增生异常综合征易感性及临床特征的相关性研究[J].现代检验医学杂志,2023,38(04):51.[doi:10.3969/j.issn.1671-7414.2023.04.009]
　XU Juana,BEN Haixianga,DING Linlina,et al.Study on the Relationship between Single Nucleotide Polymorphism of Interleukin-1β (rs16944) Gene and Susceptibility and Clinical Characteristics of Myelodysplastic Syndromes[J].Journal of Modern Laboratory Medicine,2023,38(04):51.[doi:10.3969/j.issn.1671-7414.2023.04.009]
[8]杨艳敏,郝秀君,赵志芳,等.骨髓增生异常综合征患者骨髓中ABAT mRNA表达和ABAT甲基化水平对预后预测价值研究[J].现代检验医学杂志,2024,39(06):84.[doi:10.3969/j.issn.1671-7414.2024.06.014]
　YANG Yanmin,HAO Xiujun,ZHAO Zhifang,et al.Prognostic Value of ABAT mRNA Expression and ABAT Methylation Level in Bone Marrow of Patients with Myelodysplastic Syndrome[J].Journal of Modern Laboratory Medicine,2024,39(04):84.[doi:10.3969/j.issn.1671-7414.2024.06.014]

备注/Memo

备注/Memo:
基金项目:陕西省社发攻关基金资助项目(2011K12-23)。
作者简介:韩秀蕊(1963-),女,本科,从事血液病实验室诊断及研究工作。
通讯作者:魏绪仓,研究员。
更新日期/Last Update: 2015-08-10